

The epidemiology and molecular characterization of methicillin-resistant staphylococci sampled from a healthy Jordanian population

A. G. AL-BAKRI^{1*}, H. AL-HADITHI¹, V. KASABRI², G. OTHMAN¹,
A. KRIEGESKORTE³ AND K. BECKER³

¹ Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, The University of Jordan, Amman-Jordan

² Department of Biopharmaceutics and Clinical Pharmacy, Faculty of Pharmacy, The University of Jordan, Amman-Jordan

³ Institute of Medical Microbiology, University Hospital Münster, Münster, Germany

Received 9 September 2012; Final revision 29 December 2012; Accepted 31 December 2012;
first published online 23 January 2013

SUMMARY

The prevalence of natural carriage and molecular epidemiology of methicillin-resistant *Staphylococcus aureus* (MRSA) and methicillin-resistant coagulase-negative staphylococci (MR-CoNS) isolates in a Jordanian community were investigated. The MRSA nasal carriage rate in 227 healthy volunteers was 7·5% and the majority (81%) of MRSA harboured the resistance element SCCmec type IVe and were of a novel *spa* type t9519 (76%); other significant *spa* gene types were t223 (14·7%) and t044 (5·9%). All MRSA isolates were susceptible to other classes of antibiotics, and tested positive for at least three virulence factor encoding genes, but only two harboured the *pvl* gene. MR-CoNS carriage was 54·2% and these isolates were characterized by single, double and untypable SCCmec elements, with *Staphylococcus epidermidis* SCCmec type IVa predominating. Of eight subjects with nasal co-colonization of MR-CoNS + MRSA, three shared SCCmec type IV in both groups of organisms. This is the first report of methicillin-resistant staphylococci carriage in a Jordanian community and its findings are important for epidemiological study and infection control measures of these organisms.

Key words: Jordan, MR-CoNS, MRSA, SCCmec, *spa*.

INTRODUCTION

Since the 1990s, the epidemiology of methicillin-resistant *Staphylococcus aureus* (MRSA) infections has changed markedly owing to the emergence of community-associated MRSA (CA-MRSA) infections as a serious health problem in many parts of the world [1]. Initially CA-MRSA strains were identified

as being responsible for the increase of staphylococcal infections in communities worldwide, but now they have expanded to also become a causative agent of nosocomial infections and thus the distinction between hospital- and community-acquired strains is becoming less clear [1]. Methicillin resistance in MRSA and coagulase-negative staphylococci (CoNS) is encoded by the *mecA* gene which is located within the staphylococcal cassette element (SCCmec) integrated in the bacterial chromosome [2–4]. Genotypic and phenotypic differences between CA-MRSA and hospital-acquired MRSA (HA-MRSA) strains are well

* Author for correspondence: Dr A. G. Al-Bakri, Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, The University of Jordan, Amman-Jordan.
(Email: agbakri@ju.edu.jo)

recognized and include the type of *SCCmec* element, their virulence factor profile, and wider antimicrobial susceptibility [5].

Nasal carriage of MRSA by hospital staff in Jordan was first reported in the early 1990s [6]. Subsequently, high rates of *S. aureus* (40%) and MRSA (19%) were recorded in young Jordanian adults in the community [7], which were somewhat higher than the rate (22.7%) found in a survey of 132 healthy students published 4 years earlier [8]. Recently, Khalil *et al.* [9] reported ST80-MRSA-IV as the dominant clonal type in hospitalized children in Jordan, although the extent of MRSA and MR-CoNS carriage in the healthy Jordanian community and the molecular characterization of these strains remain inadequately investigated.

A major risk factor for infections with methicillin-resistant staphylococci (MRS) is the carriage of these microorganisms at different body sites. Indeed their co-existence might facilitate the exchange of mobile resistance and other genetic elements and there is some evidence to suggest that MR-CoNS may act as a source of *SCCmec* for MRSA [4, 10, 11]. Although MR-CoNS colonization might be correlated with the emergence of MRSA, there are few epidemiological studies examining co-colonization in the healthy population for these two groups of organisms and it has been shown that there is no significant difference in terms of nasal carriage for *S. aureus* and MRSA [12] in pre-clinical and clinical university students; therefore university students are a suitable representative group on which to draw conclusions on the spread of MRSA in the wider community population [12, 13].

In the current study we aimed to determine the skin and nasal carriage rates of MR-CoNS and MRSA in healthy preclinical students and faculty staff in the Jordanian community. A secondary aim was to obtain baseline epidemiological data to inform the design and implementation of appropriate infection surveillance and control practices. Third, we investigated all isolates from the survey in detail with regard to their molecular genetic types and virulence gene profiles, and wider antimicrobial susceptibility.

METHODS

Subjects and data collection

During June 2009 to December 2009, a total of 454 microbiological samples were collected from 227

apparently healthy volunteer pharmacy students and employees at the Faculty of Pharmacy, The University of Jordan. Most (89%) of the students had not been exposed to clinical training within the 2 months prior to sampling. Written consent was obtained prior to commencing the study which complied with ethical guidelines of experimental approval (number 14/2007–2008) obtained from the Scientific Research Council at the Deanship of Academic Research, The University of Jordan. The following data were collected: demographic characteristics, medical history including previous and recent hospitalization (within a year), antibiotic consumption, and family member being a healthcare worker.

Sampling and bacteriological identification

The dorsum of the forearm (1 cm²) and the anterior nares of each volunteer subject were sampled [14] using sterile dry cotton swabs (Deltalab, Spain) pre-moistened with brain heart infusion (BHI) broth (Oxoid, UK) containing 6.5% NaCl. Each swab was immersed in the same broth and incubated at 37 °C for 2 h. The broth was subcultured onto mannitol-salt-agar (Oxoid) supplemented with methicillin (10 mg/l), and incubated at 35 °C for 24–72 h. Each distinctive colony morphotype was selected, Gram-stained and biochemically identified which included catalase (Merck, Germany), tube coagulase (Remel, UK) and DNase tests (Oxoid). Presumptive MRSA isolates (*n*=37) and randomly selected MR-CoNS isolates (*n*=51) were analysed using MICROBACT™ 12S (Oxoid) according to the manufacturer's recommendations. Isolates were stored in BHI broth supplemented with 10% glycerol, at –70 °C.

DNA extraction and PCR procedures

LB broth (Merck) overnight cultures of the MRSA and MR-CoNS isolates were prepared. Chromosomal DNA was extracted according to the manufacturer's instructions using the Wizard Genomic DNA purification kit (Promega, USA), with lysostaphin (Sigma, USA) at 25 µg/ml for the lysis step. MRSA isolates (*n*=37) and MR-CoNS isolates (*n*=298) were analysed by PCR in a PTC-100 thermocycler (MJ Research, USA) for the presence of *nuc* gene [15] and *tuf* gene [16], respectively. The multiplex PCR method [17] was used for the determination of *SCCmec* types

Table 1. Demographics of 227 healthy volunteer subjects and distribution of MRS, MR-CoNS only, MRSA only and MR-CoNS + MRSA isolates among these subjects

	MRS (<i>n</i> = 130) (57.2% of 227 participants)		MR-CoNS only (<i>n</i> = 111) (85.4% of 130 MRS)		MRSA only (<i>n</i> = 7) (5.4% of 130 MRS)		MR-CoNS + MRSA (<i>n</i> = 12) (9.2% of 130 MRS)	
	<i>n</i> (%)	<i>P</i> *	<i>n</i> (%)	<i>P</i>	<i>n</i> (%)	<i>P</i>	<i>n</i> (%)	<i>P</i>
Females	99 (76.2)		83 (74.8)		5 (71.4)		11 (91.7)	
Males	31 (23.8)		28 (25.2)		2 (28.6)		1 (8.3)	
Hospitalized	14 (10.8)	0.2	12 (10.8)	0.3	0 (0.0)	0.4	2 (16.7)	0.3
Contact with HCW	36 (27.7)	0.5	29 (26.1)	0.27	3 (42.9)	0.4	4 (33.3)	0.7
Antibiotic exposure	41 (31.5)	0.4	36 (32.4)	0.3	2 (28.6)	0.9	3 (25)	0.7

MRS, Methicillin-resistant staphylococci; MR-CoNS, methicillin-resistant coagulase-negative staphylococci; MRSA, methicillin-resistant *Staphylococcus aureus*; HCW, healthcare worker.

* Statistically significant trend (**P* < 0.05) calculated by Pearson's χ^2 test.

for all methicillin-resistant isolates and subtyping of SCC*mec* type IV was performed according to Milheirico *et al.* [18]. All MRSA isolates were analysed for the presence of Pantone–Valentine leukocidin (PVL) encoding genes (*lukS-PV*, *lukF-PV*), γ -haemolysin [19], toxic shock syndrome toxin (*tst*) and enterotoxin (*sea-see*, *seg-sej*, *sem-seo*) genes [20].

The following were used as reference strains, MRSA strains: COL, ANS46, MW2, 8/6-3P, Q2314, JCSC4469, HAR22, WIS, HDE288 [17, 18], Bk2464 [21].

spa typing of *Staphylococcus aureus*

The polymorphic X region of the *spa* gene was amplified according to Shopsis *et al.* [22]. The PCR products were purified using a PCR product purification kit (Qiagen, Germany) and DNA sequenced (Macrogen, Korea). The obtained sequences were analysed using RidomStaphType software version 2.2.1 (Ridom GmbH, Germany) and *spa* types were assigned according to the *spa* server database (<http://spaserver.ridom.de>). The relationship of the *spa* types was analysed using the BURP (based upon repeat patterns) algorithm with default parameters within the RidomStaphType software package.

Antibiotic susceptibility testing

Antibiotic susceptibility of isolates was determined using a disc diffusion method as described previously [23] with the following antibiotics (Oxoid): penicillin (10 IU), oxacillin (1 μ g) cefoxitin (30 μ g), vancomycin (30 μ g), gentamicin (10 μ g), erythromycin (15 μ g), clindamycin (2 μ g) norfloxacin (10 μ g), tetracycline

(30 μ g) and linezolid (30 μ g). MR-CoNS isolates, which were erythromycin resistant and appeared to be susceptible to clindamycin, were further tested for possible inducible clindamycin resistance as described previously [23].

Statistical analysis

Categorical variables between groups were compared by means of Pearson's χ^2 test [exact significance (two-sided)] using SPSS version 16 (SPSS Inc., USA) to evaluate the relationship between risk factors with the carriage rate of MRS, MRSA, MR-CoNS and MRSA + MR-CoNS co-colonization. A *P* value of < 0.05 was defined as significant.

RESULTS

Population characteristics

The basic demographics of the volunteers screened by nasal and skin swabs are presented in Table 1. Of 227 study participants, 173 (76.2%) were females (age range 19–26 years) and 54 were males (23%, age range 20–38 years). Twenty participants (8.8%) had been recently hospitalized. The majority (216, 95.1%) were pharmacy students and 11 (4.8%) were faculty members; 67 (29.5%) individuals had a relative working in healthcare and 67 (29.5%) had exposure to antibiotics during the study period.

Carriage rates of community MRS

Initial biochemical identification of the colonies grown from 454 samples resulted in the isolation of

Table 2. Distribution of MRSA and MR-CoNS isolates among 227 study volunteer subjects

	Subjects carrying MRSA		Subjects carrying MR-CoNS	
	<i>n</i>	(%)	<i>n</i>	(%)
Total	19	(8.4)	123	(54.2)
Total nasal	17	(7.5)	110	(48.5)
Total skin	13	(5.7)	28	(12.3)
Exclusively nasal	6	(2.6)	95	(41.8)
Exclusively skin	2	(0.9)	13	(5.7)
Nasal + skin	11	(4.8)	15	(6.6)

MRSA, Methicillin-resistant *Staphylococcus aureus*; MR-CoNS, methicillin-resistant coagulase-negative staphylococci.

335 MRS from 130/227 (57.2%) subjects (Table 1). Of these, 37 isolates were MRSA and were recovered from 16 females and three males (Table 2). The prevalence of MRSA nasal carriage was 7.5% (17/227) and 8.4% (19/227) for both nasal and extranasal colonization (Table 2). The remaining isolates (*n* = 298) were identified as MR-CoNS and were isolated from 123 participants (carriage rate 54.2%), predominantly from nasal samples (Table 2). Of the 12 individuals with MRSA and MR-CoNS carriage, nasal co-colonization was detected in eight. None of the studied risk factors was significantly correlated with carriage in either group of staphylococci (Table 1).

The species-specific *tuf* gene was identified in 152/298 MR-CoNS isolates from 87 subjects and 51 of the *tuf*-positive isolates were additionally identified by MICROBACT. Eighty percent were MR-*S. epidermidis* (MRSE) with the remainder being *S. capitis* (7.8%), *S. chromogenes* (3.9%), *S. hominis* (3.9%), *S. cohnii* (2%) and *S. haemolyticus* (2%).

Antimicrobial susceptibility

All MRSA isolates were resistant to all β -lactam antibiotics, but susceptible to all other agents tested. The majority of *tuf*-positive MR-CoNS isolates were susceptible to gentamicin (97.4%), tetracycline (90.8%), norfloxacin (84.9%), and clindamycin (79.6%). Furthermore, 52.6% showed resistance to erythromycin. Inducible clindamycin resistance was detected in 11 (7.2%) of 54 clindamycin-sensitive/erythromycin-resistant MR-CoNS isolates. All MR-CoNS were susceptible to vancomycin and linezolid.

SCCmec types for MRSA and MR-CoNS

All MRSA isolates harboured the SCCmec type IV element of subtype e (81%) and subtype c. By contrast, MR-CoNS displayed great variability in SCCmec types (Table 3). Sixty-six of 152 isolates were of a single type comprising type IV (*n* = 59, of which 53 were MRSE), type V (five MRSE) and type VI (two MRSE). Four isolates harboured two types, IV + I (three MRSE), and IV + V (one MRSE). The SCCmec element in 82 of MR-CoNS (78 MRSE) could not be identified by PCR. The identified SCCmec IV subtypes in MR-CoNS were: subtype a (56%), subtype c (5%), subtype d (1.7%), subtype e (5%), subtype g (5%) or untypable (27.1%). For non-*S. epidermidis* species only MR-CoNS-IV or MR-CoNS-NT were recognized. Significantly, 3/8 subjects colonized with both groups of staphylococci yielded isolates harbouring SCCmec type IV. The other five subjects were co-colonized by MRSA-IV either with MRSE and/or MR-CoNS of SCCmec types V and IV + I.

spa types of MRSA and virulence factors

The *spa* type of the 37 MRSA isolates and their associated virulence factors are presented in Table 4. A single novel *spa* type, designated t9519, accounted for 76% of the isolates and only two other *spa* types were identified, i.e. t223 (14.7%) and t044 (5.9%). Two isolates were positive for PVL encoding genes *lukS*-PV-*lukF*-PV and belonged to SCCmec IV subtype c, *spa* type t044. All isolates harboured γ -haemolysin and *tst* genes, and were enterotoxin-gene positive with the most common being *seb* (97.3%), *seo* (94.6%) and *sei* (91.9%). All isolates were negative for other enterotoxin genes tested: *sea*, *sec*, *sed*, *see*, *seh*, and *sej*. The PVL-positive strain carried only the *seb* gene.

DISCUSSION

Jordan had been reported as being among the countries with hyperendemic antimicrobial resistant bacterial strains. Previously, the Antibiotic Resistance in the southeastern Mediterranean (ARMed) project, reported Jordan as the country with the highest prevalence of significant clinical MRSA infections among the Mediterranean countries [24, 25]. This is expected to be correlated to antimicrobial misuse and overuse [26, 27] and probably also to a high carriage

Table 3. Distribution of SCCmec elements among 152 tuf-positive MR-CoNS from study volunteer subjects

SCCmec type	Total	<i>S. epidermidis</i>		<i>S. capitis</i>	<i>S. chromogenes</i>	<i>S. cohnii</i>	<i>S. haemolyticus</i>	<i>S. hominis</i>
		(MICROBACT + tuf)	(tuf)					
IV	59	35 (59.3)	18 (30.5)	2 (3.4)	2 (3.4)	0 (0)	0 (0)	2 (3.4)
IVa	33	20 (60.6)	11 (33.3)	2 (6.1)	0 (0)	0 (0)	0 (0)	0 (0)
IVc	3	2 (66.7)	1 (33.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
Ivd	1	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
IVe	3	1 (33.3)	2 (66.7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
IVg	3	2 (66.6)	1 (33.3)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
NT*	16	8 (50)	4 (25)	0 (0)	2 (12.5)	0 (0)	0 (0)	2 (12.5)
V	5	1 (20)	4 (80)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
VI	2	0 (0)	2 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
IV+I	3	0 (0)	3 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
IV+V	1	1 (100)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
NT†	82	4 (4.9)	74 (90.2)	2 (2.4)	0 (0)	1 (1.2)	1 (1.2)	0 (0)
Total	152		101	4	2	1	1	2

Values given are *n* (%).

* NT, Untypable by Milheirico *et al.* [18].

† NT, Untypable by Milheirico *et al.* [17].

Table 4. Resistance element, spa type and virulence gene profile patterns of MRSA carriage isolates

spa type	Isolate no.	SCCmec type	Presence (+) or absence (-) of gene								
			<i>pvl</i>	<i>haemolysin</i>	<i>tst</i>	<i>seb</i>	<i>seg</i>	<i>sei</i>	<i>sen</i>	<i>Sem</i>	<i>seo</i>
t223	3	IV†	-	+	+	+	+	+	+	+	+
T223	1	IV†	-	+	+	-	+	+	-	-	-
T223	1	IV†	-	+	+	+	-	-	-	-	+
T044	2	IV c	+	+	+	+	-	-	-	-	-
T9519	25	IV e	-	+	+	+	-	+	-	-	+
T9519	1	IV e	-	+	+	+	-	+	-	+	+
T9519	1	IV e	-	+	+	-	-	+	-	-	+
NT*	2	IV e	-	+	+	+	-	+	-	-	+
NT*	1	IV e	-	+	+	+	+	+	+	-	+

* Unable to identify the *spa* type.

† Untypable by Milheirico *et al.* [18].

rate of this microorganism. Surprisingly, we were unable to identify epidemiological factors in this study population, including antibiotic exposure or close contact with a healthcare worker, that were associated significantly with carriage of either MRSA or MR-CoNS. Of interest, the reported nasal carriage rate of MRSA found here remains unchanged from that reported previously (7.6%) in non-medical Jordanian university students [7], whereas the geographically adjacent countries of Lebanon and Saudi Arabia have reported markedly lower carriage rates of 1.6% and 1.3%, respectively [28, 29].

To the best of our knowledge, the present study is the first to comprehensively assess the genotypic and

phenotypic characteristics of MRSA isolated from healthy Jordanians in the community. Genotypically, they belonged to SCCmec type IV, a type that is often associated with CA-MRSA infections, and is also associated with a minority of hospital strains including some reported from Jordan [8, 9]. This might imply that some strains are circulating and disseminating between the hospital and community.

We report here the identification of a novel *spa* type (t9519) of MRSA with the methicillin resistance element SCCmec IVE as the predominant type carried by healthy Jordanians. BURP analysis revealed a close relationship to t012 which is a common *spa* type in Europe (spaserver.ridom.de). Interestingly, t044,

which is a widely distributed *spa* lineage of HA-MRSA in European [5] and some Middle Eastern countries, including Jordan [9, 30], was found in the present study in two healthy individuals.

The susceptibility profiles of the MRSA isolates recovered in the present study are also consistent with a community origin being susceptible to all antimicrobials with the exception of the β -lactams tested [1]. It has been suggested that antimicrobial susceptibility-based classification of CA-MRSA lacks sensitivity and the widely used marker of ciprofloxacin susceptibility may miss approximately one-third of these strains [31]. Nevertheless, PVL, a common marker of CA-MRSA, was quite rare in our isolates in accord with reports from both Japan and Ireland [32, 33]. The carriage of at least three virulence factor encoding genes suggests that the majority of our MRSA isolates have the potential to cause infections as the combinatory effect of virulence factors is strongly linked to their potential involvement in severe infections [34].

We present, for the first time, data on the prevalence and molecular epidemiology of MR-CoNS in healthy Jordanians. Consistent with previous reports, the *SCCmec* elements in MR-CoNS exhibited genetic diversity where some isolates harboured two *SCCmec* types and others were untypable [3, 35]. *SCCmec* type IV, a relatively common type in MR-CoNS of community origin [4, 35], prevailed among our *tuf*-positive MR-CoNS isolates which proved to be mostly MRSE [36]. In addition other MR species commonly isolated from human clinical specimens, such as *S. capitis*, *S. cohnii*, *S. haemolyticus* and *S. hominis*, were identified as nasal and skin colonizers. Of note, in our community pool of MR-CoNS isolates, MRSE-IV and MRSE-NT prevailed, and co-harboring of different *SCCmec* elements (MRSE-IV + V, MRSE-IV + I) was observed, a finding consistent with MRSE genome plasticity in the community [37]. In agreement with Garza-Gonzalez *et al.* [3], antibiotic susceptibility patterns in MR-CoNS isolates are diverse and this is clearly associated with the heterogeneity of *SCCmec* types present in these strains.

Resistance to β -lactams in MR-CoNS is encoded by *SCCmec* elements which have high homology with certain types of *SCCmec* of MRSA [4]. Such high homology might suggest a common origin and indicate a probable horizontal cross-transmission of resistance genes upon co-colonization [10, 11]. Thus, the sharing of the same *SCCmec* type between most of the co-colonized MRSA and MR-CoNS, might

suggest *in vivo* horizontal gene transfer but this would need to be confirmed by further genetic characterization not only of these groups but also of co-resistant methicillin-sensitive *S. aureus*.

This study has some limitations. We were not able to estimate the true prevalence of CA-MRSA infection in the general Jordanian population and wider based surveillance studies in different sections of local and regional geographical sectors are warranted to achieve this. Furthermore, the socio-demographic characteristics and the risk factors associated with MRSA acquisition were not analysed or compared with non-colonized subjects. Due to the spread of various MRSA clones between the community and hospital [38], and across national boundaries [38], a full molecular characterization of strain lineages by the internationally validated MLST system in order to define them in a global epidemiological context is of importance in both the clinical and infection control setting [39].

As successfully demonstrated in countries or regions with low, decreasing or stabilized MRSA infection rates [40], it is of utmost importance to develop comprehensive surveillance and prevention strategies that will lead to effective and robust control not only of MRSA but also other multidrug-resistant infections. Major elements of such strategies include implementation of active screening procedures adapted to the specific endemic situation, adherence to basic infection control practices, introduction and control of microorganism-specific hygiene measures, and antibiotic control programmes [41].

In conclusion, this study is the first to demonstrate a high incidence of MRS nasal and skin carriage in healthy Jordanians, a finding consistent with a community origin for these organisms. We found a high prevalence of MRSA in the community compared to other countries in the region and that most isolates are of the same genotype and share the same β -lactam antimicrobial resistance mechanism. In addition we identified nasal co-colonization with both MRSA and MR-CoNS with highly similar resistance genes in a small number of subjects which raises the possibility of horizontal resistance gene transfer between the different groups of staphylococci.

ACKNOWLEDGEMENTS

We sincerely thank Dr C. Milheiriço (Laboratory of Molecular Genetics, Universidade Nova de Lisboa, Portugal), Dr H. de Lencastre (Laboratory of

Microbiology, The Rockefeller University, New York, USA), Dr T. Ito (School of Medicine, Juntendo University, Tokyo, Japan), Dr S. Boyle-Vavra, Dr R. Daum (Department of Pediatrics, Section of Infectious Diseases, University of Chicago, USA) and Dr W. B. Grubb (Faculty of Health Sciences, Curtin University, Australia) for kindly providing the prototype and reference strains used in this study. The project was funded by the Deanship of Academic Research, The University of Jordan (grant no. 14/2007–2008) and the Scientific Research Fund, Ministry of Higher Education (grant no. 3/13/2008). Professor H. Al-Hadithi was on sabbatical leave while supervising and running this study. She is currently working in the Department Biology, Faculty of Science, University of Basrah, Iraq.

DECLARATION OF INTEREST

None.

REFERENCES

1. Yamamoto T, *et al.* Community-acquired methicillin-resistant *Staphylococcus aureus*: community transmission, pathogenesis, and drug resistance. *Journal of Infection and Chemotherapy* 2010; **16**: 225–254.
2. Ito T, *et al.* Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant *Staphylococcus aureus*. *Antimicrobial Agents and Chemotherapy* 2001; **45**: 1323–1336.
3. Garza-Gonzalez E, *et al.* Diversity of staphylococcal chromosome mec structures in coagulase-negative staphylococci and relationship to drug resistance. *Journal of Medical Microbiology* 2010; **59**: 323–329.
4. Barbier F, *et al.* Methicillin-resistant coagulase-negative staphylococci in the community: high homology of SCCmec IVa between *Staphylococcus epidermidis* and major clones of methicillin-resistant *Staphylococcus aureus*. *Journal of Infectious Diseases* 2010; **202**: 270–281.
5. Deurenberg RH, Stobberingh EE. The molecular evolution of hospital- and community-associated methicillin-resistant *Staphylococcus aureus*. *Current Molecular Medicine* 2009; **9**: 100–115.
6. Na'was T, Fakhoury J. Nasal carriage of methicillin resistant *Staphylococcus aureus* by hospital staff in Jordan. *Journal of Hospital Infection* 1991; **17**: 223–229.
7. Al-Zu'bi E, Bdour S, Shehabi AA. Antibiotic resistance patterns of mecA-positive *Staphylococcus aureus* isolates from clinical specimens and nasal carriage. *Microbial Drug Resistance* 2004; **10**: 321–324.
8. Daghistani HI, Issa AA, Shehabi AA. Frequency of nasal and wound isolates of *Staphylococcus aureus* associated with TSST-1 production in Jordanian population. *FEMS Immunology and Medical Microbiology* 2000; **27**: 95–98.
9. Khalil W, *et al.* Methicillin-resistant *Staphylococcus aureus* ST80-IV clone in children from Jordan. *Diagnostic Microbiology and Infectious Disease* 2012; **73**: 228–230.
10. Diep BA, *et al.* Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant *Staphylococcus aureus*. *Lancet* 2006; **367**: 731–739.
11. Archer GL, Niemeyer DM. Origin and evolution of DNA associated with resistance to methicillin in staphylococci. *Trends in Microbiology* 1994; **2**: 343–347.
12. Chen CS, Chen CY, Huang YC. Nasal carriage rate and molecular epidemiology of methicillin-resistant *Staphylococcus aureus* among medical students at a Taiwanese university. *International Journal of Infectious Diseases* 2012; **16**: e799–803.
13. Prates KA, *et al.* Nasal carriage of methicillin-resistant *Staphylococcus aureus* in university students. *Brazilian Journal of Infectious Diseases* 2010; **14**: 316–318.
14. von Eiff C, *et al.* Nasal carriage as a source of *Staphylococcus aureus* bacteremia. *New England Journal of Medicine* 2001; **344**: 11–16.
15. Brakstad OG, Aasbakk K, Maeland JA. Detection of *Staphylococcus aureus* by polymerase chain reaction amplification of the *nuc* gene. *Journal of Clinical Microbiology* 1992; **30**: 1654–1660.
16. Martineau F, *et al.* Species-specific and ubiquitous DNA-based assays for rapid identification of *Staphylococcus epidermidis*. *Journal of Clinical Microbiology* 1996; **34**: 2888–2893.
17. Milheirico C, Oliveira DC, de Lencastre H. Update to the multiplex PCR strategy for assignment of *mec* element types in *Staphylococcus aureus*. *Antimicrobial Agents and Chemotherapy* 2007; **51**: 3374–3377.
18. Milheirico C, Oliveira DC, de Lencastre H. Multiplex PCR strategy for subtyping the staphylococcal cassette chromosome *mec* type IV in methicillin-resistant *Staphylococcus aureus*: 'SCCmec IV multiplex'. *Journal of Antimicrobial Chemotherapy* 2007; **60**: 42–48.
19. Lina G, *et al.* Involvement of Panton-Valentine leukocidin-producing *Staphylococcus aureus* in primary skin infections and pneumonia. *Clinical Infectious Diseases* 1999; **29**: 1128–1132.
20. Jarraud S, *et al.* Relationships between *Staphylococcus aureus* genetic background, virulence factors, *agr* groups (alleles), and human disease. *Infection and Immunity* 2002; **70**: 631–641.
21. Oliveira, DC, Tomasz, A, de Lencastre H. The evolution of pandemic clones of methicillin-resistant *Staphylococcus aureus*: identification of two ancestral genetic backgrounds and the associated *mec* elements. *Microbial Drug Resistance* 2001; **7**: 349–361.
22. Shopsis B, *et al.* Evaluation of protein A gene polymorphic region DNA sequencing for typing of *Staphylococcus aureus* strains. *Journal of Clinical Microbiology* 1999; **37**: 3556–3563.

23. **Clinical Laboratory Standards Institute.** Performance standards for antimicrobial susceptibility testing: fifteenth information supplement M110-S15. CLSI, 2005, Wayne, PA, USA.
24. **Borg MA, et al.** Prevalence of methicillin-resistant *Staphylococcus aureus* (MRSA) in invasive isolates from southern and eastern Mediterranean countries. *Journal of Antimicrobial Chemotherapy* 2007; **60**: 1310–1315.
25. **Borg MA, et al.** Antibiotic resistance in the southern Mediterranean-preliminary results from the ARMed project. *Eurosurveillance* 2006; **11**: 164–167.
26. **Al-Bakri AG, Bustanji Y, Yousef AM.** Community consumption of antibacterial drugs within the Jordanian population: sources, patterns and appropriateness. *International Journal of Antimicrobial Agents* 2005; **26**: 389–395.
27. **Al-Momany NH, et al.** Adherence to international antimicrobial prophylaxis guidelines in cardiac surgery: a Jordanian study demonstrates need for quality improvement. *Journal of Managed Care Pharmacy* 2009; **15**: 262–271.
28. **Halablal MA, et al.** *Staphylococcus aureus* nasal carriage rate and associated risk factors in individuals in the community. *Epidemiology and Infection* 2010; **138**: 702–706.
29. **Alghaithy AA, et al.** Nasal carriage and antibiotic resistance of *Staphylococcus aureus* isolates from hospital and non-hospital personnel in Abha, Saudi Arabia. *Transactions of the Royal Society Tropical Medicine and Hygiene* 2000; **94**: 504–507.
30. **Tokajian ST, et al.** Molecular characterization of *Staphylococcus aureus* in Lebanon. *Epidemiology and Infection* 2010; **138**: 707–712.
31. **Otter JA, French GL.** Utility of antimicrobial susceptibility-based algorithms for the presumptive identification of genotypically-defined community-associated methicillin-resistant *Staphylococcus aureus* at a London teaching hospital. *European Journal of Clinical Microbiology and Infectious Disease* 2011; **30**: 459–463.
32. **Takizawa Y, et al.** A Panton-Valentine leucocidine (PVL)-positive community – acquired methicillin-resistant *Staphylococcus aureus* (MRSA) strain, another such strain carrying a multiple-drug resistance plasmid, and another more-typical PVL-negative MRSA strains found in Japan. *Journal of Clinical Microbiology* 2005; **43**: 3356–3363.
33. **Rossney A, et al.** The emergence and importation of diverse genotypes of methicillin-resistant *Staphylococcus aureus* (MRSA) harboring the Panton–Valentine leukocidin gene (*pvl*) reveal that *pvl* is a poor marker for community – acquired MRSA strains in Ireland. *Journal of Clinical Microbiology* 2007; **45**: 2554–2563.
34. **Peacock SJ, et al.** Virulent combinations of adhesion and toxin genes in natural populations of *Staphylococcus aureus*. *Infection and immunity* 2002; **70**: 4987–4996.
35. **Zong Z, Peng C, Lü X.** Diversity of SCCmec elements in methicillin-resistant coagulase-negative staphylococci clinical isolates *PLoS One* 2011; **6**: e20191.
36. **Ibrahim S, et al.** Carriage of methicillin-resistant Staphylococci and their SCCmec types in a long-term-care facility. *Journal of Clinical Microbiology* 2009; **47**: 32–37.
37. **Lebeaux D, et al.** Evolution of nasal carriage of methicillin-resistant coagulase-negative staphylococci in a remote population. *Antimicrobial Agents and Chemotherapy* 2012; **56**: 315–323.
38. **Song JH, et al.** Spread of methicillin-resistant *Staphylococcus aureus* between the community and the hospitals in Asian countries: an ANSORP study. *Journal of Antimicrobial Chemotherapy* 2011; **66**: 1061–1069.
39. **Mediavilla JR, et al.** Global epidemiology of community-associated methicillin resistant *Staphylococcus aureus* (CA-MRSA). *Current Opinion in Microbiology* 2012; **15**: 588–595.
40. **Ammerlaan HS, et al.** Eradication of carriage with methicillin-resistant *Staphylococcus aureus*: effectiveness of a national guideline. *Journal of Antimicrobial Chemotherapy*. 2011; **66**: 2409–2417.
41. **Huskins WC, et al.** Intervention to reduce transmission of resistant bacteria in intensive care. *New England Journal of Medicine* 2011; **364**: 1407–1418.